Who is sponsoring NCT03262311?

NCT03262311 is sponsored by Institute of Cancer Research, United Kingdom.

What is the status of NCT03262311?

NCT03262311 is currently COMPLETED.

Last reviewed 2019-12-23 · How we verify

Pimo Study: Extracellular Vesicle-based Liquid Biopsy to Detect Hypoxia in Tumours

NCT03262311 NA COMPLETED

The purpose of this study is to test the potential of a relatively simple serum assay that aims to identify patient subpopulations whose curative radiotherapy outcome is likely to be compromised by radiobiological tumour hypoxia (prognostic value) and who are most likely to gain (predictive value) from the addition of radiation sensitiser drugs or targeted radiotherapy dose escalation.

Details

Lead sponsor	Institute of Cancer Research, United Kingdom
Phase	NA
Status	COMPLETED
Enrolment	21
Start date	Fri Nov 10 2017 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Thu Sep 12 2019 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

Cancer

Interventions

Hypoxia marker

Countries

United Kingdom